top of page

News

NEWSLETTER

Inaugural newsletter

April 2024

We are pleased to share the first edition of the LEAP4WA newsletter. The dedication and ingenuity of all involved in LEAP4WA is laying the groundwork for the advanced clinical testing of the LASV vaccine candidate, with preparations underway to start the LEAP4WA trial in the coming 12 months. In the meantime, thanks to the hard work of the partners and clinical trial sites, the Phase 2a trial (funded by CEPI) is now underway following approval by the Ethics and Regulatory authorities in Nigeria, Liberia, and Ghana.


Click here for updates on the broader clinical development programme of the LASV vaccine candidate, meet the LEAP4WA students, and learn about LEAP4WA’s site preparation work.

NEWS FROM THE FIELD

As CEPI ramps up vaccine research, a new study warns Lassa fever is set to expand its reach across Africa

CEPI  |  11 October 2022

Climate change and other environmental factors could cause Lassa fever to spread to additional regions within Africa, new research predicts. Read the full article here.

IAVI announces first vaccinations at Liberia site in Phase 1 clinical trial of Lassa fever vaccine candidate

IAVI  |  31 August 2022

The trial is designed to evaluate the candidate’s safety, tolerability, and immunogenicity. Read the full press release here.

EDCTP and CEPI funding moves IAVI’s Lassa fever vaccine candidate into advanced clinical development

IAVI  |  14 June 2021

IAVI has received an award of €22.8 million from the European & Developing Countries Clinical Trials Partnership (EDCTP) and the Coalition for Epidemic Preparedness Innovations (CEPI) to conduct a Phase IIb clinical trial of a novel vaccine candidate to prevent Lassa fever disease.. Read the full press release here.

IAVI and the Public Health Agency of Canada Enter into License Agreement for Technology to Enable Lassa Fever Vaccine Development

IAVI  |  14 August 2018

IAVI to apply expertise in viral vector vaccines to Lassa Fever prevention effort. Read the full press release here.

CEPI Partners with IAVI to Advance Lassa Fever Vaccines

IAVI  |  21 May 2018

The Coalition for Epidemic Preparedness Innovations (CEPI) and IAVI announce partnership to develop a Lassa fever vaccine. Read the full press release here.

A Spiking Fever

Science  |  22 February 2024

Read this article in Science for a recent commentary on surging cases of Lassa fever in West Africa and efforts across the field to tackle this growing health threat.

bottom of page